nowagron - definitely no problem with your perspective and facts.....anyone who would be surprised if we were to decline is not being realistic.
We are definitely not a hospital supply company......we are definitely not a traditional biotech (FORTUNATLEY NOT THE CASH BURN AND FDA UPS & DOWNS)......we are a hybrid with lots of institutional ownership / guys that understand we will grow with the AMGN's, BIIB, CELG, GILD, etc. as their market, business and media requirements grow / we are nimble enough and own the patents for the columns and manufacturing and da cash to acquire......WE RULE ALONG WITH THE BIOTECHS'S!
We will know the reason they sold shares at the first Q conf call - everything else is speculation like 1) biotechs are rich 2) RGEN is a little rich / like many others 3) management is rewarding themselves 4) management is diversifying their portfolio like other intelligent investors.....but could be any above.
Very minor and totally expected cash out a few shares for retirement....he has about 450,000 remaining shares......common wake up.....no biggie at all!
Zacks is simply an opinion based on technicals / definitely not propaganda....the charts do say overbought but this could rebound in a few days or few weeks.....today it appears biotechs are getting slammed and contrary to what one poster says about RGEN not being a biotech we are fortunately categorized and linked to and trade along with BIOTECHS and that is very positive!.
Those of us who are long either sell a few or as usual stick it out and lets see what the market thinks about the first Q that is going to be very strong.
RESPECTFULLY - if all that has been written that you can readily access for the past several months is not
enough of an explanation then nothing more could possibly be written to calm your fears of a high PE & share price.....and many of us know and understand the multiple is a bit rich but not totally unusual either.
Chartgirl nailed it......mucho buyers......on volume.......institutions are new owners providing a very
strong base over $30......not allot of sellers as owners value shares and love the growth guidance
Respectfully some have answered and responded and offered their opinions to help you understand the
value / market cap / share price / future / cash / etc etc but with no skin in the game you continue to jerk yourself off!
As expected the buying and da chart were screaming positive market results based on the year
and the Q......and again to dudobug:
Respectfully some have answered and responded and offered their opinions to help you understand the value / market cap / share price / future / cash / etc etc but with no skin in the game you continue to jerk yourself off!
Respectfullly some have answered and responded and offered their opinions to help you understand the value / market cap / share price / future / cash / etc etc but with no skin in the game you continue to jerk yourself off!
Continues to hold up very well.....tomorrow tomorrow.....exciting!
Some of us are concerned with the PE but so many biotech's wish they even had a PE.....may underwater
at the mercy of the FDA as WE USED TO BE.....NOW A GROWTH STOCK WITH THE MARKET POSSIBLY PRICING AS A BUYOUT CANDIDATE IN 2016.
Thanks - understand.....but I have RARELY SEEN A 3 FOR 1 ON A $25 PRICE STOCK??
Was this anything you read or simply throwing the idea out for discussion?
jb - where did this stock split idea come from....does not change the valuation on a PE basis......what value
would this bring to RGEN?
Interesting that the chart and the buying going into Fridays year end and Q is holding up well - its saying we will
not see a dip......ultimately no one knows and we wait until Friday.
Will be interesting and exciting.....guidance as important as numbers....but 3 out 4 earnings were not
great for share price so we wait.....some may bet against this short term trade but long term would never
bet against beloved RGEN! Would not be surprised to see a dip and then next week and announcement
of acquisition that would more than make up the dip.
we have seen 3 out of the last earning reports cause a dip in share price so this should be interesting.
The good news is we have rebounded after each dip / some took time. Would not be surprised if we test $20ish again.....
HOPE TO BE TOTALLY WRONG.